The company’s lead investigational therapy, tanruprubart ... the potential approval of ANX005 for Guillain-Barré Syndrome (GBS) and the safety and activity of ANX1502 in Cold Agglutinin ...

to stop C1q activity in the peripheral and central nervous systems; the clinical and regulatory status of ANX005; and the potential therapeutic benefit of ANX005; the potential benefits from treatment ...

Annexon’s lead investigational therapy, tanruprubart, is a first-of-its kind selective, targeted and rapid-acting agent designed to reduce inflammation and nerve damage by stopping C1q activity ...

(MENAFN- GlobeNewsWire - Nasdaq) First Oral Presentation by the International Guillain-Barré Syndrome ... the potential benefits from treatment with anti-C1q therapy; and continuing advancement ...

First Oral Presentation by the International Guillain-Barré Syndrome Outcomes ... the potential benefits from treatment with anti-C1q therapy; and continuing advancement of the company’s ...